US 11,884,699 B2
Anti-KIT antibodies and uses thereof
Yaron Hadari, Harrison, NY (US); Elizabeth M. Mandel-Bausch, Pleasant Prairie, WI (US); Susanne Radke, Hamden, CT (US); Joseph Schlessinger, Woodbridge, CT (US); and Yoshihisa Suzuki, Hamden, CT (US)
Assigned to Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed by Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed on Aug. 14, 2020, as Appl. No. 16/994,164.
Application 16/994,164 is a division of application No. 16/214,980, filed on Dec. 10, 2018, granted, now 10,793,639.
Application 16/214,980 is a division of application No. 15/361,936, filed on Nov. 28, 2016, granted, now 10,189,907, issued on Jan. 29, 2019.
Application 15/361,936 is a division of application No. 13/981,852, granted, now 9,540,443, issued on Jan. 10, 2017, previously published as PCT/US2012/022471, filed on Jan. 25, 2012.
Claims priority of provisional application 61/537,482, filed on Sep. 21, 2011.
Claims priority of provisional application 61/507,430, filed on Jul. 13, 2011.
Claims priority of provisional application 61/436,483, filed on Jan. 26, 2011.
Prior Publication US 2020/0385483 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01); C12N 9/24 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); G01N 33/573 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); C07K 16/2803 (2013.01); C12N 9/2497 (2013.01); G01N 33/573 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/912 (2013.01)] 20 Claims
 
1. A method for treating or managing rheumatoid arthritis, inflammatory bowel disease, asthma, allergic inflammation, a gastrointestinal disorder or mastocytosis, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof, which immunospecifically binds to human KIT and comprises:
(i) a variable light (“VL”) chain region comprising a VL CDR1, VL CDR2, and VL CDR3 comprising the amino acid sequences of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, respectively; and
(ii) a variable heavy (“VH”) chain region comprising a VH CDR1, VH CDR2, and VH CDR3 comprising the amino acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively.